PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMoxifloxacin
Moxifloxacin
Moxifloxacin, Vigamox (moxifloxacin) is a small molecule pharmaceutical. Moxifloxacin was first approved as Avelox on 1999-12-10. It is used to treat bacterial infections, bacterial pneumonia, bacteroides infections, bronchitis, and cystitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
urogenital diseasesD000091642
Trade Name
FDA
EMA
Moxifloxacin, Vigamox (discontinued: Avelox, Moxeza, Moxifloxacin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Moxifloxacin hydrochloride
Tradename
Company
Number
Date
Products
MOXIFLOXACIN HYDROCHLORIDEFresenius KabiN-205572 RX2015-04-03
1 products, RLD, RS
VIGAMOXHarrowN-021598 RX2003-04-15
1 products, RLD, RS
Show 3 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aveloxNew Drug Application2011-12-13
avelox abc packNew Drug Application2009-10-25
dex-moxiunapproved drug other2020-02-10
dex-moxi pfunapproved drug other2018-05-08
dex-moxi-ketorunapproved drug other2020-02-10
dexmoxiketor pfunapproved drug other2018-05-08
ixoba munapproved drug other2021-11-03
moxezaNew Drug Application2021-08-11
moxifloxacinANDA2025-09-19
moxifloxacin hydrochlorideANDA2025-10-01
Show 8 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
urinary tract infectionsEFO_0003103D014552N39.0
sinusitisEFO_0007486D012852J32
bacterial infections—D001424A49
gonorrheaDOID_7551D006069A54
pseudomonas infectionsEFO_0001076D011552A41.52
escherichia coli infectionsEFO_1001318D004927B96.20
bronchitis—D001991J40
streptococcal infectionsEFO_1001476D013290—
bacterial pneumoniaEFO_1001272D018410J15.9
staphylococcal infections—D013203A49.01
Show 8 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Moxifloxacin Hydrochloride, Moxeza, Harrow Eye
84503112029-05-29DP
91141682029-05-29DP
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01M: Quinolone antibacterials
— J01MA: Fluoroquinolone antibacterials, systemic
— J01MA14: Moxifloxacin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AE: Fluoroquinolone antiinfectives, ophthalmologic
— S01AE07: Moxifloxacin
HCPCS
Code
Description
J2280
Injection, moxifloxacin, 100 mg
J2281
Injection, moxifloxacin (fresenius kabi) not therapeutically equivalent to j2280, 100 mg
Clinical
Clinical Trials
672 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
NeoplasmsD009369—C801————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMoxifloxacin
INNmoxifloxacin
Description
Moxifloxacin is a quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents. It has a role as an antibacterial drug. It is a quinolinemonocarboxylic acid, a quinolone, a member of cyclopropanes, a pyrrolidinopiperidine, an aromatic ether, a quinolone antibiotic and a fluoroquinolone antibiotic. It is a conjugate base of a moxifloxacinium(1+).
Classification
Small molecule
Drug classantibacterials (quinolone derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
Identifiers
PDB—
CAS-ID151096-09-2
RxCUI—
ChEMBL IDCHEMBL32
ChEBI ID63611
PubChem CID152946
DrugBankDB00218
UNII IDU188XYD42P (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Moxifloxacin
+
Dexamethasone
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Moxifloxacin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 27,008 documents
View more details
Safety
Black-box Warning
Black-box warning for: Avelox, Avelox abc pack, Moxifloxacin hydrochloride, Moxifloxacin hydrochloride tablets, 400 mg
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
33,415 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use